Clinical Trial Update: Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing Actovegin for post-stroke cognitive impairment has completed and results were posted in 2016. The trial evaluated efficacy and safety wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-stroke Cognitive Impairment

Drugs mentioned

• Actovegin

Snippet

Sponsor: Takeda | Conditions: Post-Stroke Cognitive Impairment (PSCI) | Phase 3 | Status: COMPLETED | Results posted: 2016-02-22